🔗 Share this article

While America proceeds with historic revisions to its vaccination schedules, a particular individual has emerged unexpectedly: Tracy Beth Høeg, a Danish American physician and epidemiologist who rose to prominence by casting doubt on Covid shots during the global health crisis and has focused upon possible deaths after COVID-19 immunization in her recent time at the Food and Drug Administration.

Scheduled Overhauls to Pediatric Immunization Schedule

Public health authorities planned to reveal radical revisions to the pediatric vaccination calendar in December, aligning the US with Denmark’s national calendar, sources say – a major change that would place the US out of step with many the world with little proof for benefit. The announcement has been pushed back until the next year.

In place of the director of the vaccine center, Dr. Høeg is listed to address the audience at the event. She was just designated interim head of the FDA’s drug evaluation center, the fifth person to lead the division this year.

A New Direction at the Agency

The acting appointment may indicate a tighter collaboration between the pharmaceutical and vaccine branches as Høeg and Dr. Prasad consolidate power at the agency – and it suggests a renewed priority upon dismantling long-standing immunizations at the FDA.

The new acting director has frequently advocated for discontinuing specific pediatric immunization guidelines in the US in order to be more similar to the Danish model, a country with universal health coverage and a population approximately the population of Wisconsin’s.

To date public appearances, she has persisted in emphasizing on immunizations – typically the responsibility of Prasad, head of the FDA’s vaccine center – instead of pharmaceutical oversight.

Doubts Over Expertise

Høeg has no obvious track record in pharmaceutical research, oversight or management, which has been standard for previous leaders of the CBER. She has worked at the FDA as a top consultant to the agency head and the vaccine center since March.

“She doesn’t seem to have any of the qualifications” for overseeing the CDER, remarked a neurologist and psychiatrist. “She lacks experience running a clinical trial. She lacks experience in running a major agency. She is not an expert in drug approvals.”

Previous commissioners of CBER would “understand laws and regulations and the science of drug development”, noted a former acting FDA commissioner. “Objectively, she has not acquired the sort of resume that previous people who headed the center have had.”

The drug center has an enormous workload at the FDA, she pointed out.

“The public just pays attention on the innovative therapies, but the off-patent medication office approves thousands of generic medications. There’s a biosimilars program, OTC medication office and other areas, and all of those need to be supervised,” Woodcock said. “The area you neglect, that is the part that I always told people is going to bite you.”

Additionally, a substantial administrative aspect to the role, which supervises in excess of 5,000 staff members. “It is a massive leadership role, if you do it right,” she concluded.

Response and Disputed Initiatives

Regarding concerns about Høeg’s credentials and whether this selection signifies more teamwork among FDA leaders on immunizations, a press secretary said that the “inquiries stem from flawed assumptions”.

“Her experience is consistent with the responsibilities of her job,” the spokesperson stated, citing the months Dr. Høeg spent guiding the FDA commissioner on “pharmaceutical safety and regulatory science, including predictive safety algorithms and vaccine surveillance”.

In her interim role, Dr. Høeg inherits the commissioner’s controversial expedited review system, a contentious rapid therapy clearance system that reportedly troubled her predecessors. “By what process are these drugs being chosen for this voucher program? Who makes the decisions?” Howard asked. “There’s a lot of lack of transparency going on at the FDA right now.”

Broadly speaking, he stated, “the FDA looks to be trending towards less stringent regulations of pharmaceuticals, aside from immunizations.”

Established Track Record on Vaccines

Concerning vaccines, Dr. Høeg has a clearer, if troubling, track record, Howard observe. She published a research paper using non-validated crowd-sourced reports to determine the incidence of heart inflammation after COVID-19 vaccination. She advised the state of Florida chief medical officer Dr. Joseph Ladapo, who reportedly have altered data to indicate Covid vaccines are riskier than they are.

Among her “wish list” for the incoming federal leadership encompassed revising rules for novel immunizations and discontinuing “non-essential” immunizations, she remarked following the vote on a online show. At the FDA, Høeg has allegedly proposed preventing young men from obtaining Covid vaccines.

“She is an thorough dogmatist who commences with her beliefs and tailors the evidence to accommodate the data in a extremely deceptive, fraudulent fashion,” Dr. Howard said.

Taking Control and a “Campaign of Retribution”

Dr. Høeg joined other dissenters, {like|